- Home
- AHMA vs KZIA Comparison
AHMA vs KZIA Comparison
Compare AHMA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHMA | KZIA |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United Arab Emirates | Australia |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 161.5M |
| IPO Year | 2025 | 1999 |
Fundamental Metrics
Financial Performance| Metric | AHMA | KZIA |
|---|---|---|
| Price | $7.09 | $15.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 2.8M | 1.9M |
| Earning Date | 12-08-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $18,543,447.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $213.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.00 | $2.86 |
| 52 Week High | $18.20 | $22.60 |
Technical Indicators
Market Signals| Indicator | AHMA | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 73.02 |
| Support Level | N/A | $7.68 |
| Resistance Level | N/A | $17.40 |
| Average True Range (ATR) | 0.00 | 2.30 |
| MACD | 0.00 | 0.73 |
| Stochastic Oscillator | 0.00 | 82.25 |
Price Performance
Historical ComparisonAbout AHMA Ambitions Enterprise Management Co. L.L.C Class A Ordinary Shares
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.